SevenBridge Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

SevenBridge Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,076	Closed	-$333K	–	225
2024 Q3	$333K	Buy	6,076 +425	+8%	+$21.6K	0.06%	175
2024 Q2	$279K	Hold	5,651	–	–	0.06%	176
2024 Q1	$316K	Sell	5,651 -625	-10%	-$44.7K	0.07%	168
2023 Q4	$393K	Hold	6,276	–	–	0.09%	139
2023 Q3	$285K	Hold	6,276	–	–	0.07%	153
2023 Q2	$352K	Buy	6,276 +100	+2%	+$5.67K	0.09%	142
2023 Q1	$279K	Sell	6,176 -125	-2%	-$6.07K	0.08%	154
2022 Q4	$256K	Buy	6,301 +525	+9%	+$27.9K	0.07%	159
2022 Q3	$377K	Hold	5,776	–	–	0.13%	121
2022 Q2	$351K	Buy	5,776 +807	+16%	+$47.4K	0.14%	105
2022 Q1	$312K	Sell	4,969 -30	-0.6%	-$1.88K	0.11%	125
2021 Q4	$379K	Sell	4,999 -593	-11%	-$51.8K	0.11%	123
2021 Q3	$626K	Hold	5,592	–	–	0.21%	99
2021 Q2	$905K	Buy	5,592 +117	+2%	+$14.2K	0.3%	87
2021 Q1	$667K	Hold	5,475	–	–	0.24%	95
2020 Q4	$838K	Buy	+5,475	New	+$647K	0.33%	81

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SevenBridge Financial Group's CRSP Position: Q4 2024 in Review

SevenBridge Financial Group sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 6,076 shares — an estimated $333K sold.

SevenBridge Financial Group first reported a position in CRSP in Q4 2020 and held it in 16 quarters. The position peaked at $905K in Q2 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

SevenBridge Financial Group reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
SevenBridge Financial Group sold 6,076 CRISPR Therapeutics shares in Q4 2024, an estimated $333K.
SevenBridge Financial Group first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 16 quarters.
SevenBridge Financial Group's CRISPR Therapeutics position peaked at $905K in Q2 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on SevenBridge Financial Group's 13F filing for Q4 2024, filed 12 Feb 2025.